Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Beth Israel Deaconess Medical Center
With
The Broad Foundation
Brigham and Women's Hospital
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
CD confirmed by biopsy for \> 3 months duration
Active disease (Harvey-Bradshaw Index \> 5
Failed standard therapy with; stable doses of 5-ASA \>2 weeks; thiopurines \>3 months; or is steroid dependent at a dose \<20mg/d; (inability to taper off steroid for longer than 1 week)
Stable medication regimen for \>2 weeks.
Age \> 18 years old
You may not be if
Diagnosis of indeterminate colitis, or proctitis alone
Severe or fulminate colitis
Women who are pregnant or nursing
Patients who are unable to give informed consent
Patients who are unable or unwilling to undergo colonoscopy with moderate sedation (\>ASA class II)
Patients who have previously undergone FMT
Patients who have a confirmed malignancy or cancer
Patients who are immunocompromised
Treatment within last 12 weeks with cyclosporine, tacrolimus, infliximab, adalimumab, certolizumab, natalizumab, thalidomide
Antibiotic use within 2-months of start date
Participation in a clinical trial in the preceding 30 days or simultaneously during this trial
Probiotic use within 30 days of start date
Rectal therapy within 14 days of start date
Decompensated cirrhosis
Congenital or acquired immunodeficiencies
Other comorbidities including:
Diabetes mellitus, cancer, systemic lupus, must be able to tolerate conscious sedation with colonoscopy
Chronic kidney disease as defined by a GFR \<60mL/min/1.73m2 44
History of rheumatic heart disease, endocarditis, or valvular disease due to risk of bacteremia from colonoscopy
